09995 榮昌生物
按盘价 
16.740 -1.320 (-7.309%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | -26.170% | -19.623% | 6.675% | -29.034% | -70.514% |
| 股东资金回报率 (%) | -35.907% | -23.706% | 7.847% | -41.504% | N/A |
| 资本运用回报率 (%) | -34.419% | -19.475% | 7.798% | -18.930% | N/A |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 76.477% | 64.841% | 95.283% | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -118.521% | -112.899% | 25.215% | N/A | N/A |
| 税前边际利润率 (%) | -140.432% | -130.094% | 19.401% | N/A | N/A |
| 纯利率 (%) | -140.432% | -130.094% | 19.401% | N/A | N/A |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 1.959 X | 3.600 X | 3.731 X | 6.903 X | 0.161 X |
| 速动比率 (X) | 1.308 X | 3.014 X | 3.276 X | 6.750 X | 0.124 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 37.823% | 17.287% | 17.138% | 12.703% | 133.652% |
| 总债项 / 总资产比率 (%) | 22.792% | 2.741% | 2.471% | 4.801% | 9.483% |
| 净债项 / 总资产比率 (%) | 9.649% | -31.624% | -39.768% | -62.434% | 4.471% |
| 总债项 / 股东资金比率 (%) | 36.657% | 3.314% | 2.982% | 5.500% | N/A |
| 长期债项 / 股东资金比率 (%) | 26.628% | 2.106% | 1.460% | 1.296% | N/A |
| 净债项 / 股东资金比率 (%) | 15.519% | -38.234% | -47.993% | -71.519% | N/A |
| 净现金 / (债项) ($) | (5.33亿) | 19.04亿 | 16.54亿 | 25.71亿 | (3.08千万) |
| 每股净现金 / (债项) ($) | (0.980) | 3.499 | 3.377 | 7.188 | -- |
| 总债项 / 资本运用比率 (%) | 28.697% | 3.218% | 2.901% | 5.363% | N/A |
| 利息盈利率 (X) | N/A | N/A | 52.899 X | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 911.457日 | 542.882日 | 941.583日 | -- | -- |
| 应收贸易帐周转率日数 (日) | 118.985日 | 68.514日 | 1.807日 | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 61.226日 | 90.552日 | 28.441日 | N/A | N/A |
| 备注： | 实时报价更新时间为22/11/2024 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -780,460,000 |
| 增长率 | 10.961% |
| 每股盈利/(亏损) | RMB -1.450 |
| 每股账面资产净值 (¥) | RMB 4.895 |